An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Study sponsor: Avalyn Pharma Inc. · AVLN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2031-12-31Estimated
Enrollment · participants340Estimated
Source updated2026-11-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.